Compare Eli Lilly And Co (LLY) vs Sea Limited (SE) Price & Performance

Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.

LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.

Sea Limited (SE) trades at $92.89, down 1.87% on the day, as technical indicators signal bearish momentum with the stock testing key support levels. Fundamentally, the company shows strong revenue growth with 2025 revenue reaching $22.94 billion and net income of $1.58 billion, though recent Q4 2025 earnings missed expectations. Analyst sentiment remains overwhelmingly positive with 31 buy ratings and a consensus price target of $153.67, representing significant upside potential from current levels.

The investment case hinges on Sea's continued e-commerce and fintech expansion, with Shopee's growth and Monee's profit potential driving long-term value. However, risks include competitive pressures, margin compression concerns, and recent insider selling activity. The current price decline presents a potential buying opportunity for investors believing in Sea's Southeast Asia growth story, though volatility may persist near-term.